Summary. von Willebrand factor (VWF) is a key player in hemostasis, acting as a carrier for factor VIII and capturing platelets at sites of vascular damage. To capture platelets, it must undergo conformational changes, both within its A1 domain and at the macromolecular level through A2 domain unfolding. Its size and this function are regulated by the metalloproteinase ADAMTS-13. Recently, it has been shown that ADAMTS-13 undergoes a conformational change upon interaction with VWF, and that this enhances its activity towards its substrate. This review summarizes recent work on these conformational transitions, describing how they are controlled. It points to their importance in hemostasis, bleeding disorders, and the developing field of therapeutic application of ADAMTS-13 as an antithrombotic agent in obstructive microvascular thrombosis and in cardiovascular disease.

Keywords: ADAMTS-13; conformational activation; hemostasis; TTP; VWF.

Introduction

Von Willebrand factor (VWF) is a large and heterogeneous, multidomain adhesive glycoprotein (GP) (Fig. 1A) that is essential for normal hemostatic function. It is synthesized in endothelial cells (and megakaryocytes) as a monomer that dimerizes in the endoplasmic reticulum through a C-terminal disulfide bond [1]. Multimerization occurs in the Golgi, resulting from propeptide-induced disulfide bond formation [2,3]. Numerous and complex glycan chains are added during synthesis [4,5]. Heterogeneous VWF and ultralarge VWF (ULVWF) are stored within Weibel–Palade bodies, from which they can be released constitutively and upon demand [6]. The ULVWF released into the circulation is potentially toxic, because, unprocessed, it is able to spontaneously interact with platelets, forming clumps that can block the microcirculation [7]. The pioneering work of Furlan et al. and Tsai et al. in 1996 identified a VWF-processing plasma protease with unusual properties, Zn$^{2+}$ and Ca$^{2+}$ dependencies, with an (in vitro) requirement for substrate denaturation prior to cleavage [8,9]. The VWF-cleaving protease is able to reduce the size and hemostatic function of VWF in vivo by controlled cleavage at a single, specific site (its scissile bond, Tyr1605-Met1606) within the VWF A2 domain. The resultant processed VWF circulates as a folded, quiescent and globular protein, which is heterogeneous with respect to its size. Despite this quiescent state, it is able to recognize and bind to collagen exposed by vascular injury through its A3 domain [10,11]. Shear stress unfolding of the protein then reveals the platelet capture site, on the A1 domain, enabling primary hemostasis with the formation of the initial platelet plug [12].

The major motivation for understanding the function of the VWF-cleaving protease came from the demonstration that its deficiency was the cause of the fatal disease thrombotic thrombocytopenic purpura (TTP) [13–15] and from the identification of its gene, designated ADAMTS13 [16–20] (Fig. 1B). ADAMTS-13 was recognized as a metalloproteinase family member, with Glu225 at its active site, requiring Zn$^{2+}$ occupancy of three His residues to confer functionality to the proteinase domain [21]. Its function also depends on Ca$^{2+}$, and a high-affinity functional Ca$^{2+}$-binding site has been identified near the active site [22]. In the past 15 years, the role(s) of many of the domains of ADAMTS-13 have been elucidated. What has also emerged is the pivotal role of the ADAMTS-13–VWF axis in regulating hemostasis. Severe deficiency of ADAMTS-13, either congenital or acquired, can result in excess ULVWF and causes TTP. Furthermore, there is increasing evidence suggesting that even a moderate decrease in ADAMTS-13 activity can also predispose to cardiovascular disease. Regional domain mutation of VWF, on the other hand, increases proteolytic

Correspondence: David A. Lane, Commonwealth Building 5S5, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
Tel.: +44 20 8383 2298
E-mail: d.lane@imperial.ac.uk

Received: 19 June 2017
Manuscript handled by: W. Ruf
Final decision: P. H. Reitsma, 25 October 2017

© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
susceptibility to ADAMTS-13, causing a bleeding disorder, type 2A von Willebrand disease (VWD).

A number of reviews have summarized the progress in understanding the basic mechanisms of ADAMTS-13–VWF interactions or their role in disease [23–33]. The aims of this review are to provide an update of recent mechanistic work, focusing particularly on the dynamics of interaction, and then to summarize recent experimental and clinical investigations that point to possible therapeutic roles for ADAMTS-13.

Shear-induced conformational unfolding of VWF

The transition of VWF by shear stress from its quiescent, compact folded state to an elongated platelet capture protein is central to its function. Interest has focused on the VWF A2 domain, as this has an obvious structural adaptation allowing response to shear, i.e. its lack of a domain-spanning disulfide bond. A pioneering single-molecule pulling and relaxing study of the isolated A2 domain employed double-stranded DNA handles coupled to beaded tags and optical tweezers, with laser trap detection of force changes induced with a micropipette [34]. This demonstrated A2 unfolding at a force of \(~10\) pN. Subsequent studies of incorporation of the A2 domain into an A1–A2–A3 domain construct found doubling of the force required for unfolding [35,36]. Remarkably, force-induced unfolding completely extends the A2 domain from 1 nm (the distance between the N-terminus and the C-terminus) to 58 nm, a similar length to that of the resting VWF monomer. This large extension is accompanied by accelerated cleavage of the domain in the presence of ADAMTS-13 (see below), arising from exposure of the otherwise hidden exosites that bind ADAMTS-13 and also exposure of the cleavage site. This sequence of unfolding, extension and cleavage has been elegantly demonstrated by the use of VWF strings under flow [37]. As force is relaxed, the domain can spontaneously refold, restricting the action of ADAMTS-13 [34].

The three principal structural elements controlling A2 domain unfolding and refolding have been identified, and are shown in Fig. 2. An unusual disulfide bond between two vicinal cysteines, Cys1669 and Cys1670, at the C-terminus was identified in a crystal structure [38]. It was proposed that this bond forms a hydrophobic plug that could improve thermal stability and protect against shear unfolding, inhibiting proteolysis by ADAMTS-13, a suggestion that was subsequently confirmed [39]. An alternative crystal structure identified a Ca\(^{2+}\)-binding site formed by Asp1596, Arg1597, Ala1600, and Asn1602 [40]. Full occupancy of this site in blood is predicted by its micromolar affinity for Ca\(^{2+}\). With the use of single-molecule optical tweezers, force-induced transitions in unfolding and refolding of the A2 domain were shown to depend on occupancy of this Ca\(^{2+}\)-binding site. The third important structure controlling unfolding is the N-linked glycan at Asn1574. Early studies of the action of ADAMTS-13 against VWF had...
This figure was generated in PyMOL by use of the VWF A2 domain with Tyr1544 in the adjacent loop (both residues shown in black). GlcNAc moiety (gray) of the N-linked glycan at Asn1574 interacts © of a cryptic binding site within the A1 domain, and that LRP1 recognition of VWF is dependent on the exposure of shear stress, and therefore concluded that unfolding (LRP1) scavenger receptor, was dependent on the presence of macrophages, through the LDL receptor-related protein 1 (LRP1) scavenger receptor, was dependent on the presence of cation-dependent binding between D4 domains [46]. It is conjectured that initial VWF unfolding arises within the A2 domain, and that the additional length of the molecule is then exposed to a dramatic increase in hydrodynamic force that can subsequently trigger dimer unfolding and full unfolding of VWF [46].

Conformational activation of ADAMTS-13 by VWF

The study of ADAMTS-13 function has been greatly facilitated by the use of truncation mutants, prepared mostly from constructs with progressive deletion from the C-terminus. The early study of Gao et al. revealed that cleavage of the short VWF73 substrate was enhanced approximately four-fold when full-length (FL) ADAMTS-13 was truncated to its MDTCS variant [47]. This finding suggested that the distal domains comprising thrombospondin (TSP) repeats and CUB domains might autoinhibit the activity of the molecule, a suggestion that was pursued in two recent studies. Muia et al. first used activity assays to determine the effect of pH on ADAMTS-13 activity [48]. They found that FL ADAMTS-13, but not the truncated MDTCS variant, was most active at pH 6. Furthermore, they observed that mAbs directed at the C-terminal domains of ADAMTS-13 could enhance ADAMTS-13 activity only at pH 6. This suggested an autoinhibitory role for the C-terminal domains at physiologic pH. In addition to decreased pH and the presence of activating mAbs, this autoinhibition was also shown to be relieved by the presence of the C-terminal D4 domain of VWF. Interestingly, proteolytic fragments of the VWF D4 domain were unable to activate ADAMTS-13, suggesting the presence of more than one ADAMTS-13-binding site within the D4 domain, an idea that will be returned to below. Using small-angle X-

© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
ray scattering measurements of ADAMTS-13 and its truncated variants, Muia et al. suggested that ADAMTS-13 has a folded domain structure, with maximum dimensions that are compact as compared with those suggested by molecular models of extended ADAMTS-13. This was further supported by electron microscopy (EM), which showed ADAMTS-13 in both compact and elongated conformations [48].

South et al. approached the same issue by study of a gain-of-function (GoF) ADAMTS-13 spacer domain variant (Tyr568Lys/Phes92Tyr/Arg660Lys/Tyr661Phe/Tyr665Phe, originally described by Jian et al. [49]), that shows enhanced activity as compared with wild-type (WT) ADAMTS-13. Using functional assays in the presence and absence of the ADAMTS-13 C-terminal binding fragment of VWF, VWF D4-CK, they showed that VWF binding to WT ADAMTS-13 resulted in its unfolding and functional activation [50]. However, the GoF variant was found to be in a preactivated state, and could not be further activated by VWF D4-CK. Direct binding between the spacer domain of the ADAMTS-13 N-terminal fragment, MDTCS, and a CUB1–2 domain fragment was also demonstrated. It was proposed that it is this interaction that maintains the closed conformation of ADAMTS-13 and is disrupted in the GoF variant (Fig. 3A). Interestingly, the GoF variant residue substitutions were engineered at residues that were recognized by autoantibodies causing acquired TTP. It appears that these antigenic determinants are normally masked by CUB binding to the spacer domain, and are only revealed during conformational activation (Fig. 3F). Extensive EM analysis, generating class averages of ~6000 particles, confirmed that WT ADAMTS-13 adopts a compact, globular conformation that is partially relieved in the GoF variant [50].

The activation of ADAMTS-13 by the VWF D4-CK fragment highlights the important role of the C-terminal domains of VWF in its proteolytic processing. Two prior studies had identified the involvement of this region of globular VWF in the recognition of ADAMTS-13. Using a combination of binding techniques and functional assays, Zanardelli et al. had identified an ADAMTS-13-binding site in VWF D4-CK, largely preserved within the D4 domain, that they claimed functioned to approximate the two proteins in the absence of conformational activation of VWF [51]. Feys et al. used complementary approaches, including immunoprecipitation, to show reversible association of ADAMTS-13 with globular VWF [52]. In both investigations, the binding interaction was estimated to be of modest affinity, i.e., ~80 nm, and a stoichiometry of approximately one ADAMTS-13 molecule to 250 VWF molecules was suggested [51,52]. At the time of these reports, it was believed that this binding was primarily for positioning of the two, in readiness for shear-induced VWF unfolding, in order for cleavage to occur efficiently. In the light of the above recent work demonstrating conformational activation of ADAMTS-13, the binding reaction can also be viewed as inducing an activation step to prepare ADAMTS-13 for its exosite interactions with the shear-induced unfolded VWF A2 domain (see also below). In the circulation, only 3% of ADAMTS-13 is thought to be bound to globular VWF [52], presumably in a conformationally active state. Under thromboinflammatory conditions, during which VWF is released from Weibel–Palade bodies of the activated endothelium, or is tethered to the exposed subendothelium, the proportion of conformationally active ADAMTS-13 may be much higher.

The demonstration of conformational activation of ADAMTS-13 prompted an investigation by Deforche et al. of the flexibility of the distal ADAMTS-13 domains [53]. They generated a series of mAbs with differing specificities. One of these recognized a normally hidden epitope in the proximal domains that was exposed by activating anti-ADAMTS-13 antibodies. This was used to probe the role of three linker regions within the distal TSP2–CUB2 domains that contributed to the structural flexibility needed to accommodate the changes from compact to more elongated shapes during the activation process. Deletion of these linker regions resulted in increased recognition of the cryptic epitope, indicative of an open conformation and therefore enhanced activity of ADAMTS-13.

The work of South et al. has refined the model of ADAMTS-13 conformational activation and the mechanism by which the autoinhibitory CUB–spacer domain interaction is interrupted by binding of the VWF D4-CK domains [54]. Using direct binding analysis (surface plasmon resonance [SPR]), they first determined that both the CUB1 domain and the CUB2 domain bind to exosite 3 of the spacer domain. Both of these interactions are abolished in the GoF variant. The orientation of the CUB domains is such as to allow both CUB1 and CUB2 to interface with Arg568, Phe592, Arg660, Tyr661, and Tyr665 (Fig. 3B). Only the isolated CUB1 domain has an inhibitory effect in activity assays of MDTCS, which is in agreement with this model, in which it is positioned in close proximity to the key residues Tyr661 and Tyr665. South et al. next addressed the question of how VWF D4-CK binding disrupts the closed conformation of ADAMTS-13 [54]. It was determined, with SPR, that a VWF D4-CK domain fragment binds with moderate affinity to both CUB1 and CUB2 (Fig. 3C). This suggested that binding of the VWF C-terminal domains may compete with the CUB–spacer domain interaction. However, removal of the CUB domains did not abolish binding of VWF D4-CK to ADAMTS-13. An explanation for this was provided when they showed that TSP8 is a major binding partner of VWF D4-CK, and that this binding interaction is essential for conformational activation (Fig. 3D). This new model of activation, with binding
of VWF D4-CK to TSP8, CUB1, and CUB2, confirms the functional importance of the flexible linker region L3 described by Deforche et al. (Fig. 3E). This new model also supports the idea, suggested by Muia et al., that VWF D4 contains multiple binding motifs for ADAMTS-13 [48].
The transition from compact to elongated structures has brought to the fore the intriguing issue of the restricted specificity of ADAMTS-13. It is interesting that this metalloproteinase has only a single known function, that of cleavage of VWF. Other than suggested inhibition of ADAMTS-13 by neutrophil peptides [55], there are no known physiologic inhibitors to regulate its action. It is rare that proteases are completely specific for a single substrate, and local factors, such as regional concentrations of protease and substrate, can determine whether there is sufficient availability to allow proteolysis to occur. Promiscuity may therefore be expected. The entire range of possible residue changes that permit proteolysis of the small VWF substrate VWF73 has been mapped by use of a substrate phage display library [56,57]. This has highlighted the importance of the scissile bond residues as well as previously identified exosite regions (see below), but has also demonstrated that, within these regions, many possible residue substitutions that permit cleavage are possible. This suggests that sequence similarities found within other proteins might encourage their cleavage. To explore this, South et al. recently investigated whether the compact structure of ADAMTS-13 might restrict its substrate specificity. In the course of flow experiments, in which VWF/fibrinogen-containing pseudothrombi were lysed by ADAMTS-13, it was found that fibrinogen could also be cleaved by the protease, under circumstances in which the protective spacer–CUB interaction was prevented or disrupted [58]. They have shown that unfolded, activated ADAMTS-13 (GoF ADAMTS-13, the truncated variant MDTCS and WT ADAMTS-13 activated by VWF D4-CK) can directly cleave the Aβ chain of fibrinogen, rendering fibrin formed in thrombi more prone to lysis by the fibrinolytic system. The sequence surrounding the cleavage site in the Aβ chain resembled, but was not identical to, the cleavage site in VWF. It was therefore suggested that conformational quiescence of ADAMTS-13 may help to protect against off-target proteolysis.

This study has generated some debate regarding the secondary proteolytic potential of ADAMTS-13. In a letter to the Journal of Thrombosis and Haemostasis, Cao and Zheng suggested that proteolysis of fibrinogen by ADAMTS-13 is indirect, and occurs because of the generation of plasmin [59]. However, as described by South et al. in their reply, the proteolysis observed in the original study occurred at a single site of the Aβ chain, and was not sensitive to either PPACK or tranexamic acid [60]. Therefore, in these experiments, extensive plasminogen activation had not occurred. In work carried out subsequent to the original study, Cao et al. proposed that conformationally active ADAMTS-13 can indeed proteolyze plasminogen, generating functional plasmin, similarly to tissue-type plasminogen activator (t-PA) [61]. It is therefore possible that conformationally active ADAMTS-13 may have more than one secondary substrate, and that it may play a dual role in the fibrinolytic system. It could act directly on fibrinogen, removing the Aβ-antiplasmin-binding site and rendering fibrin more susceptible to the action of plasmin, while simultaneously upregulating the generation of plasmin through its proteolytic activity against plasminogen. Unlike the secondary activity of plasmin against VWF, which has been suggested to be a natural backup during periods of ADAMTS-13 deficiency [62], the physiologic relevance of ADAMTS-13 secondary activity is yet to be established. Further work is required to confirm some of these suggestions, which may be an important consideration in the development of ADAMTS-13 variants as therapeutic agents (see below).

Preactivated ADAMTS-13 variants may have disadvantages in the therapeutic context. If their improved recognition by TTP autoantibodies [50] is not diminished by prior mutation, there may be increased clearance/inhibition by TTP autoantibodies, particularly when they are administered to TTP patients with persisting, circulating inhibitory antibodies [63]. The finding that 5% of healthy (non-TTP) individuals are positive for circulating low-affinity anti-ADAMTS-13 IgG autoantibodies [64] may suggest that administration of preactivated ADAMTS-13 in other indications should be approached cautiously. Nevertheless, unlike for VWF, there is no evidence that the ADAMTS-13 conformation affects its cellular, non-autoantibody-mediated clearance. Although there is an obvious glycan-dependent difference in the half-life of ADAMTS-13 (expressed in different cell lines) when it is injected into mice [65,66], there is no observable difference between the half-lives of FL ADAMTS-13 and its truncation variants T8 and S (which are presumably conformationally active) when they are used in animal models [66]. In individuals with no circulating ADAMTS-13 autoantibodies, it is therefore likely that the therapeutic administration of preactivated ADAMTS-13 would result in enhanced cleavage of ULVWF.

Exosite interactions leading to cleavage of the VWF scissile bond

The force-induced unfolding of the VWF A2 domain reveals cryptic exosites that progressively increase the affinity of binding between ADAMTS-13 and VWF. The earliest characterized of these was that contained within the VWF sequence, i.e. Glu1660–Arg1668 [67,68]. This exosite interacts with the spacer domain of ADAMTS-13, i.e. Arg568, Arg660, Tyr661, and Tyr665, which is the antigenic region recognized by autoantibodies generated in patients with acquired TTP [69,70] (see also the GoF ADAMTS-13 variant mentioned above). An important additional exosite was then located within the unfolded VWF A2 domain by De Groot et al., who demonstrated an interaction of Asp1614 of VWF with ADAMTS-13 disintegrin domain residue Arg349 [71].

The deletion mutagenesis approaches used by Gao et al. had suggested that the Cys-rich domain of ADAMTS-13 might enhance its interaction with unfolded
VWF [47], but the mechanism of this was not fully defined until recently. De Groot et al. used a targeted glycan incorporation approach to narrow the region on the Cys-rich domain that might be involved [72]. By substituting residues close to a glycan-modified residue at position 476 that inhibited activity and binding to VWF, they identified a hydrophobic pocket containing Gly471–Val474 that interacts with an exosite in the unfolded VWF A2 domain. This exosite is composed of the hydrophobic residues Ile1642, Trp1644, Ile1649, Leu1650, and Ile1651. Disruption of the exosite by substitution with hydrophilic residues reduced the catalytic efficiency of cleavage of VWF substrates ~12-fold [72].

As well as increasing the affinity of the interaction between ADAMTS-13 and VWF, these exosites help to bring the active site of the metalloproteinase domain into proximity with the VWF scissile bond. For proteolysis to occur, P1 Tyr1605 and P1′ Met1606 of the VWF substrates must engage with the S1 and S1′ subsites on the face of the active site of the protease. This engagement requires a hydrophobic interaction between VWF P3 Leu1603 and hydrophobic ADAMTS-13 residues, possibly Leu198, Leu232, and Leu274, collectively forming the S3 subsite [73].

The potential clinical importance of conformational dynamics

Bleeding disorders, type 2A VWD, and acquired von Willebrand syndrome

The importance of the dynamic control of ADAMTS-13 and VWF is well illustrated in patients with the bleeding disorder type 2A VWD, who carry mutations causing residue substitutions within the VWF A2 domain. Numerous disease-causing mutations are located within the 175 residues of the domain. Such mutations can result in impaired secretion of VWF [74] (termed type 2A group 1) or increase the susceptibility of VWF to proteolysis by ADAMTS-13 [75] (type 2A group 2). Mutations also cause both phenotypes [76]. These phenotypes arise directly as a consequence of the conformational flexibility of the A2 domain conferred by the absence of a domain-spanning disulfide bond: without the rigidity provided by the domain-spanning disulfide bond, the A-domain fold is readily disrupted, causing either increased cellular retention or cleavage [77]. Although the three stabilizing features described above, i.e. the vicinal cysteines, Ca2+-binding site, and N-linked glycan at Asn1574, provide some resistance to spontaneous unfolding, the A2 domain appears to be unable to retain its natural fold under the additional pressure of residue substitutions. Because many of these mutations disrupt the stability of the A2 domain conferred by the three structural elements, allowing unfolding and exposure of the exosite binding sites for ADAMTS-13, they thereby facilitate proteolysis of the scissile bond. Mutations occur throughout the domain and, regardless of their position or nature, there can be enhanced proteolysis, depleting ULVWF multimers and predisposing to or causing bleeding [78,79].

A second example of disruption of the normal interaction of VWF and ADAMTS-13 is provided by acquired von Willebrand syndrome associated with a left ventricular assist device (LVAD), recently reviewed by Nascimbeni et al. [80]. LVADs were introduced for use in patients awaiting heart transplantation, to provide temporary artificial circulatory improvement. Shear forces within these devices or their connecting tubes may exceed that of the normal circulatory system. VWF may be abnormally stretched or induced to bind to the surface of the biomaterials components and then to unfold. Excessive unfolding would be expected to be accompanied by increased proteolytic action by ADAMTS-13. Although direct evidence of enhanced ADAMTS-13 activity is currently lacking, it is evident that there is a reduction in the level of ULVWF multimers in patients with LVADs [80]. This reduction in the level of multimers could contribute to the complex hemostatic problems (bleeding, in particular) that may be experienced by users of LVADs.

TTP

The activating conformational change in ADAMTS-13 induced by VWF can be predicted to be important in TTP. Both congenital and acquired TTP are characterized by low levels of circulating ADAMTS-13 and the subsequent formation of VWF/platelet-rich microthrombi in the microvasculature. The acquired form of the disease results from the formation of autoantibodies against ADAMTS-13, which can be inhibitory but can also decrease ADAMTS-13 antigen levels through increased clearance from the circulation [81]. Many of the most common autoantibody epitopes are found within the crucial spacer domain exosites of ADAMTS-13. South et al. demonstrated that one of these epitopes, comprising Arg568, Phe592, Arg660, Tyr661 and Tyr665 in exosite 3 of the spacer domain, was recognized more readily by the patient-derived mAb II-1 (first described by Pos et al. [82]) upon conformational activation of ADAMTS-13 [50]. Masking of cryptic epitopes in the closed conformation of ADAMTS-13 may prevent autoantibody formation. A compact structure of plasma ADAMTS-13 may explain the low immunogenicity of ADAMTS-13 administered as replacement with fresh frozen plasma to TTP patients with congenital deficiency.

For autoantibody development, cryptic epitopes may become exposed. Increased levels of plasma VWF during pregnancy or infection, which are common clinical triggers of acquired TTP, might lead to substrate-induced activation of ADAMTS-13 and antigenic exposure. Recently, Verbij et al. found that CD4+ T cells from
acquired TTP patients were reactive to CUB2 domain-derived peptides [83], the sequences of which are found on the exposed surface of CUB2 in the current model of the activated ADAMTS-13 structure (Fig. 3). The presence of antibodies against the constitutively exposed C-terminus of ADAMTS-13 could be the result of epitope spreading, subsequent to initial immune recognition of newly exposed cryptic epitopes. In another study, in which a panel of mAbs against ADAMTS-13 were generated, numerous antibodies, targeted at the C-terminal domains of ADAMTS-13, were identified that enhance its activity to a level that indicates conformational activation [53]. Therefore, early antigenic recognition of ADAMTS-13 may occur through surface-exposed epitopes within the C-terminal domains. The potential activating effect of these antibodies may lead to further exposure of the N-terminal domain epitopes and the development of an inhibitory autoantibody population. This may be compatible with the development of anti-ADAMTS-13 IgG in healthy individuals [64]. The study by Grillberger et al. [64] suggested that low-affinity, non-inhibitory antibodies, some of which were targeted to the C-terminal domains of ADAMTS-13, may precede the memory B-cell hypermutation needed for the generation of high-affinity (and possibly activating) antibodies. It will be interesting to determine whether the normally compact structure of ADAMTS-13 is perturbed during acute episodes of acquired TTP.

In mouse models of congenital TTP, in which ADAMTS13−/− mice are challenged with recombinant VWF [84], the administration of recombinant ADAMTS-13 (rADAMTS-13) ameliorates TTP. Animal models of antibody-mediated acquired TTP have been developed by inducing ADAMTS-13 deficiency in mice, rats and baboons by the use of inhibitory mAbs [63,85,86]. In these models, the clinical features of TTP manifest because of an increase in the circulating ULVWF level. Agents that target ULVWF may therefore have prophylactic value. This has been shown in mice by the use of streptokinase-induced plasmin generation and in baboons by the use of N-acetylcysteine, both of which reduce ULVWF multimer levels [62,87]. In a rat model of TTP, the administration of rADAMTS-13 was able to overcome the presence of the inhibitory autoantibodies and degrade ULVWF multimers [63]. These animal studies show a clear protective effect of rADAMTS-13 therapy in both genetically determined and acquired TTP. Two other therapeutic agents, caplacizumab and the aptamer ARC1779, which target the collagen–VWF–GP1b axis, have shown promise in phase II clinical trials of acquired TTP [88,89]. Collectively, these studies argue for the potential of targeting VWF with rADAMTS-13 as a treatment for TTP. This has recently been supported by a phase I clinical trial in congenital TTP patients, in which rADAMTS-13 effectively reduced the size of circulating VWF multimers [90].

**VWF–ADAMTS-13 dynamics in cardiovascular disease**

The dynamics of both VWF and ADAMTS-13 are of potential importance in cardiovascular diseases and their management. It has been suggested that imbalance of their plasma levels (low ADAMTS-13 and high VWF) might predispose to cardiovascular disease, particularly myocardial infarction (MI) and ischemic stroke (IS) [91,92]. A number of case-control, prospective and meta-analysis studies have supported this suggestion [93–98]. A study by Bongers et al. also established a strong association between ADAMTS-13/VWF levels and both coronary heart disease and peripheral arterial disease [99]. A possible pathogenic role of VWF/ADAMTS-13 in atherosclerosis has also been suggested. A strong association was identified between high levels of VWF and the progression of atherosclerosis in IS patients [100], and, more recently, VWF was suggested as a predictor of coronary plaque burden and cardiovascular outcome in patients with acute coronary syndrome and stable angina pectoris [101]. Whether a low ADAMTS-13 level might be a risk factor for atherosclerotic plaque progression [102] requires further study.

The above studies of cardiovascular disease were largely conducted by measurement of antigen or simple function assays of ADAMTS-13 levels, as it is impractical to measure ULVWF levels and the conformational state of ADAMTS-13 in large studies. To establish whether the moderate changes in VWF and ADAMTS-13 levels, which appear to be risk factors for IS and MI, are further influenced by the dynamic interplay between the two will require the development of new analytic approaches. Further insights into the roles of the ADAMTS-13–VWF axis in cardiovascular diseases, and the potential of rADAMTS-13 as a therapeutic agent, have been obtained with experimental models, some of which are summarized below.

**Animal models of IS and MI**

The pivotal work performed by Zhao et al. [65] and Gandhi et al. [103] established the importance of VWF and ADAMTS-13 in the pathophysiology of IS and MI by using VWF−/− and ADAMTS13−/− mice. Using a transient middle cerebral artery occlusion (tMCAO) model of cerebral ischemia, Zhao et al. demonstrated that VWF deficiency, in both VWF+/− and VWF−/− mice, resulted in a reduction in infarct volume [65]. Conversely, ADAMTS-13 deficiency caused an increase in infarct volume. This was directly attributed to the loss of its action on VWF, as the infarct volumes in VWF+/ADAMTS13−/− mice were similar to those observed in VWF+/− mice. These findings were mirrored in the study performed by Gandhi et al. [103], in which ADAMTS-13 deficiency was found to increase infarct size, and exacerbate the resulting functional deficit, following acute myocardial ischemia/
reperfusion (I/R) injury in mice [103]. Again, this was attributed to the action of ADAMTS-13 on VWF, as infarct size was reduced to a similar extent in both VWF<sup>−/−</sup> and VWF<sub>ADAMTS13</sub>−/− mice.

Importantly, in both investigations, the detrimental effect of ADAMTS-13 deficiency was relieved by targeting VWF, either with neutralizing mAbs [103], or by the administration of rADAMTS-13 [65]. The administration of rADAMTS-13 to WT mice undergoing tMCAO did not induce cerebral hemorrhage and did not sensitize mice in the thrombocytopenia-induced intracerebral hemorrhage model [65]. The precise mechanism by which rADAMTS-13 protects against ischemic injury remains uncertain. The finding that rADAMTS-13 administration does not increase bleeding time to the same extent as VWF deficiency [65] suggests that reduction of ULVWF levels, rather than VWF antigen depletion, may be responsible. It is likely that rADAMTS-13 can lyse existing thrombi and prevent the formation of further thrombi by decreasing the level of circulating ULVWF. The protective role of rADAMTS-13 in myocardial I/R injury was also demonstrated in the study by De Meyer et al. [104]. In this study, the detrimental effect of ADAMTS-13 deficiency on infarct size in a mouse model of acute myocardial I/R injury was demonstrated. Furthermore, it was shown that rADAMTS-13 administration to WT mice resulted in reduced infarct size, reduced myocardial apoptosis, and reduced neutrophil infiltration into the damaged myocardium [104]. Again, no potential hemorrhagic risk or bleeding tendency was observed in animals treated with rADAMTS-13.

The therapeutic potential of rADAMTS-13 for the treatment of IS has been investigated [105]. It has been suggested to be able to circumvent two of the major limitations associated with t-PA. First, the administration of rADAMTS-13 did not induce the blood–brain barrier destabilization and hemorrhagic risk normally associated with t-PA [105]. Second, rADAMTS-13 appears to have a longer therapeutic time window than t-PA, as reduced infarct size was observed in animals treated with ADAMTS-13 when it was administered up to 4 h after injury [106]. Denorme et al. have examined the composition of thrombi recovered from patients suffering acute cerebral ischemia [107]. They found that these clots varied in composition, with the VWF content varying from 6% to 49%. This may account for instances of t-PA-refractory occlusions in patients with stroke. Using the focal ischemia mouse model, in which middle cerebral artery occlusion is largely VWF-dependent, they confirmed that VWF-rich thrombi are t-PA-resistant. They were able to demonstrate a significant, and dose-dependent, reduction in infarct size and increased recanalization upon administration of rADAMTS-13. This thrombolytic effect was also partially maintained when ADAMTS-13 administration was delayed by 1 h.

**Summary**

Growing clinical and experimental evidence suggests the importance of the VWF–ADAMTS-13 axis not only in hemostasis, bleeding disorders, and TTP, but also in cardiovascular disease. The improved knowledge of the dynamics of interactions may first impact on the understanding of these complex diseases, and then also offer the potential for improved interventions.

**Addendum**

K. South and D. A. Lane designed, wrote and reviewed the article.

**Acknowledgements**

This work was supported by British Heart Foundation grants PG/12/55/29740 and FS/14/21/30733 awarded to D. A. Lane and PG/14/87/31181 awarded to K. South and D. A. Lane.

**Disclosure of Conflict of Interests**

The authors state that they have no conflict of interest.

**References**

1. Marti T, Rosselet SJ, Titani K, Walsh KA. Identification of disulphide-bridged substructures within human von Willebrand factor. *Biochemistry* 1987; 26: 8099–109.
2. Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. *Cell* 1988; 52: 229–36.
3. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. *Proc Natl Acad Sci USA* 1992; 89: 3531–5.
4. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler JE, Fujikawa K. Amino acid sequence of human von Willebrand factor. *Biochemistry* 1986; 25: 3171–84.
5. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. *BLOOD* 2008; 111: 3042–9.
6. Wagner DD, Saffaripour S, Bonfanti R, Sadler JE, Cramer EM, Chapman B, Mayadas TN. Induction of specific storage organelles by von Willebrand factor propolypeptide. *Cell* 1991; 64: 403–13.
7. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. *N Engl J Med* 1982; 307: 1432–5.
8. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by *in vivo* proteolysis. *Blood* 1996; 87: 4223–34.
9. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. *Blood* 1996; 87: 4235–44.
Mohri H, Yoshioka A, Zimmerman TS, Ruggeri ZM. Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites. J Biol Chem 1989; 264: 17361–7.

Roth GJ, Titani K, Hoyer LW, Hickey MJ. Localization of binding sites within human von Willebrand factor for monoclonic type III collagen. Biochemistry 1986; 25: 8357–61.

Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppel SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939–50.

Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097–103.

De Meyer SF, Denome F, Langhauer F, Geuss E, Fluri F, Kleinschmit C. Thromboinflammation in stroke brain damage. Stroke 2016; 47: 1165–72.

Akyol O, Akyol S, Chen CH. Update on ADAMTS13 and VWF in cardiovascular and hemodislogical disorders. Clin Chim Acta 2016; 463: 109–18.

Kramer Hovinga JA, Coppo P, Lammle B, Mouke JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017; 3: 17020.

Cataland SR, Wu HM. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use. J Thromb Haemost 2015; 13(Suppl. 1): S223–9.

Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014; 164: 759–66.

Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009; 324: 1350–4.

Ying J, Ling Y, Westfield LA, Sadler JE, Shao JY. Unfolding the A2 domain of von Willebrand factor with the optical trap. Biophys J 2010; 98: 1685–93.

Wu T, Lin J, Cruz MA, Dong JF, Zhu C. Force-induced cleavage of single VWF:A2A3 tridomains by ADAMTS-13. Blood 2010; 115: 370–8.

De Ceunynck K, Rocha S, Feyes HB, De Meyer SF, Uji-i H, Deckmyn H, Hofkens J, Vanhoorelbeke K. Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem 2011; 286: 36361–7.

Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci USA 2009; 106: 9226–31.

Luken BM, Winn LY, Emsley J, Lane DA, Crawley JT. The importance of vicinal cysteines, C1669 and C1670, for von Willebrand factor A2 domain function. Blood 2010; 115: 4910–13.

Jakobi AJ, Mashaghi A, Tans SJ, Huizinga EG. Calcium modulates force sensing by the von Willebrand factor A2 domain. Nat Commun 2011; 2: 385.

Lynch CJ, Lane DA. N-linked glycan stabilization of the VWF A2 domain. Blood 2016; 127: 1711–18.

Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059–63.

Anderson PJ, Kokame K, Sadler JE. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006; 281: 850–7.

Gardner MD, Chion CK, de Groot R, Shah A, Crawley JT, Lane DA. A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood 2009; 113: 1149–57.

Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212–21.

Zheng XL. Structure-function and regulation of ADAMTS-13 protease. J Thromb Haemost 2013; 11(Suppl. 1): 11–23.

Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112: 11–18.

Zander CB, Cao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol 2015; 22: 452–9.

De Meyer SF, Stoll G, Wagner DD, Kleinschmit C. von Willebrand factor: an emerging target in stroke therapy. Stroke 2012; 43: 599–606.

De Ceunynck K, De Meyer SF, Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood 2013; 121: 270–7.
48 Muia J, Zhu J, Gupta G, Haberichter SL, Friedman KD, Feys HB, Deforche L, Vanhoorebeke K, Westfield LA, Roth R, Tolia NH, Heuser JE, Sadler JE. Allosteric activation of ADAMTS13 by von Willebrand factor. *Proc Natl Acad Sci USA* 2014; 111: 18584–9.

49 Cao W, Zander CB, Zheng XL. Distal carboxyl-terminal domain activation of ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. *Blood* 2012; 119: 3836–43.

50 South K, Luken BM, Crawley JT, Phillips R, Thomas M, Collins RF, Deforche L, Vanhoorebeke K, Lane DA. Conformational activation of ADAMTS13. *Proc Natl Acad Sci USA* 2011; 111: 18578–83.

51 Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, Tseng M, Lane DA. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. *Blood* 2009; 114: 2819–28.

52 Feys HB, Anderson PJ, Vanhoorebeke K, Majerus EM, Sadler JE. Multi-step binding of ADAMTS-13 to von Willebrand factor. *J Thromb Haemost* 2009; 7: 2088–95.

53 Deforche L, Roose E, Vandenbulcke A, Vandeputte N, Feys HB, Springer TA, Mi LZ, Muia J, Sadler JE, Soejima K, Rottersteiner H, Deckmyh H, De Meyer SF, Vanhoorebeke K, Linker domains and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13. *J Thromb Haemost* 2015; 13: 2063–75.

54 South K, Freitas MO, Lane DA. A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. *J Biol Chem* 2017; 292: 5760–9.

55 Pillai VG, Bao J, Zander CB, McDaniel JK, Chetty PS, Secholzer SH, Bdeir K, Cines DB, Zheng XL. Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. *Blood* 2016; 128: 110–19.

56 Desch KC, Kretz C, Yee A, Gildersleeve R, Metzger K, Agrawal N, Cheng J, Ginsburg D. Probing ADAMTS13 substrate specificity using phage display. *PLoS ONE* 2015; 10: e0122931.

57 Kretz CA, Dai M, Soylemez O, Yee A, Desch KC, Siemeniak D, Tomberg K, Kondrashov FA, Meng F, Ginsburg D. Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13. *Proc Natl Acad Sci USA* 2015; 112: 9328–33.

58 South K, Freitas MO, Lane DA. Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity. *J Thromb Haemost* 2016; 14: 2011–22.

59 Cao WJ, Zheng XL. Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: comment. *J Thromb Haemost* 2017; 15: 586–9.

60 South K, Freitas MO, Lane DA. Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: reply. *J Thromb Haemost* 2017; 15: 589–90.

61 Cao W, Zander CB, Zheng XL. Distal carboxyl-terminal domains of ADAMTS13 determine its substrate specificity. *Blood* 2016; 128: 1383.

62 Tersteeeg C, de MaaT S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorebeke K, de Groot PG, Maas C. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. *Circulation* 2014; 129: 1320–31.

63 Tersteeeg C, Schiviz A, De Meyer SF, Plaimauer B, Scheifflinger F, Rottensteiner H, Vanhoorebeke K. Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. *Arterioscler Thromb Vasc Biol* 2015; 35: 2336–42.

64 Grillberger R, Casina VC, Turecek PL, Zheng XL, Rottensteiner H, Scheifflinger F. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura. *Haematologica* 2014; 99: e58–60.

65 Zhao BQ, Chauhan AK, Canault M, Patten IS, Yang JJ, Doekel M, Scheifflinger F, Wagner DD. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. *Blood* 2009; 114: 3329–34.

66 Xiao J, Jin SY, Xue J, Sorrillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. *Arterioscler Thromb Vasc Biol* 2011; 31: 2261–9.

67 Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. *Proc Natl Acad Sci USA* 2006; 103: 19099–104.

68 Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. *Proc Natl Acad Sci USA* 2006; 103: 18470–4.

69 Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. *Blood* 2010; 115: 1640–9.

70 Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg (659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. *Blood* 2010; 115: 2300–10.

71 de Groot R, Bardhan A, Ramroop N, Lane DA, Crawley JT. Essential role of the disintegrin-like domain in ADAMTS13 function. *Blood* 2009; 113: 5609–16.

72 de Groot R, Lane DA, Crawley JT. The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysis. *Blood* 2015; 125: 1968–75.

73 Xiang Y, de Groot R, Crawley JT, Lane DA. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13). *Proc Natl Acad Sci USA* 2011; 108: 11602–7.

74 Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. *J Biol Chem* 1992; 267: 4424–30.

75 Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). *J Clin Invest* 1986; 77: 947–51.

76 Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. *Blood* 2012; 119: 4543–53.

77 Xu AJ, Springer TA. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain. *J Biol Chem* 2013; 288: 6317–24.

78 Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillcrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rocchi F, Schneckheimer R, Ruggeri ZM, Srivastava A, Montgomery RR, et al., Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *J Thromb Haemost* 2006; 4: 2103–14.

79 Hassensophagium, Buddle U, Obser T, Angerhaus M, Drewe E, Schneppenheim S, Schneppenheim R. Impact of mutations in
the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. *Blood* 2006; 107: 2339–45.

80 Nasimbene A, Neelamgah S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. *Blood* 2016; 127: 3133–41.

81 Thomas MR, de Groot R, Scully MA, Crawley JT. Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. *Ebiomedicine* 2015; 2: 942–52.

82 Pos W, Luken BM, Kremer Hovinga JA, Turenhout EA, Schefflinger F, Dong JF, Fijnheer R, Voorberg J. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost* 2009; 7: 421–8.

83 Verbij FC, Turksma AW, de Heij F, Kajien P, Lardy N, Fijnheer R, Sorello V, ten Brinke A, Voorberg J. CD4 T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides. *Blood* 2016; 127: 1606–9.

84 Schiviz A, Piskernik C, Dietrich B, Hoellriegl W, Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Feys HB, Roodt J, Vandeputte N, Lamprecht S, van Deforche L, Tersteeg C, Roose E, Vandenbulcke A, Vandeputte J. ADAMTS13. *Arterioscler Thromb Vasc Biol* 2016; 36: 2446–51.

85 Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, Rottensteiner H, Schefflinger F, Koudstaal PJ, Ikram MA, Leebeek FW. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. *Blood* 2015; 126: 2739–46.

86 Denorme F, Krafft P, Pareyn I, Drechsler C, Deckmyn H, Vanhooorebeke K, Kleinschnitz C, De Meyer SF. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. *PLoS ONE* 2017; 12: e0179258.

87 Bongers TN, de Brijne EL, Dippel DW, de Jong AI, Deckers JW, Poldermans D, de Maat MP, Leebeek FW. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. *Atherosclerosis* 2009; 207: 250–4.

88 Sonneveld MA, van Dijk AC, van den Herik EG, van Loon JE, de Lau LM, van der Lugt A, Koudstaal PJ, de Maat MP, Leebeek FW. Relationship of Von Willebrand factor with carotid artery and aortic arch calcification in ischemic stroke patients. *Atherosclerosis* 2013; 230: 210–15.

89 Sonneveld MA, Cheng JM, Oemrawsingh RM, de Maat MP, Kardys I, Garcia-Garcia HM, van Geuns RJ, R sagar E, Serruys PW, Boersma E, Akkerhuis KM, Leebeek FW. Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study. *Thromb Haemost* 2015; 113: 577–84.

90 Gandhi C, Ahmad A, Wilson KM, Chauhan AK. ADAMTS13 modulates atherosclerotic plaque progression in mice via a VWF-dependent mechanism. *J Thromb Haemost* 2014; 12: 255–60.

91 Gandhi C, Motto DG, Jensen M, Lentz SR, Chauhan AK. ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. *Blood* 2012; 120: 5224–30.

92 De Meyer SF, Savchenko AS, Haas MS, Schatzberg D, Carroll MC, Chiviz A, Dietrich B, Rottensteiner H, Schefflinger F, Wagner DD. Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice. *PLoS ONE* 2017; 12: e0179258.

93 Wang L, Fan W, Cai P, Fan M, Zhu X, Dai Y, Sun C, Cheng Y, Zheng P, Zhao BQ. Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice. *Ann Neurol* 2013; 73: 189–98.

94 Nakano T, Irie K, Hayakawa K, Sano K, Nakamura Y, Tanaka M, Yamashita Y, Satho T, Fujioka M, Muroi C, Matsuo K, Ishikura H, Futagami K, Mishima K. Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication. *Brain Res* 2015; 1624: 330–5.

95 Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, Francois O, Andersson T, Schefflinger F, Kleinschnitz C, Vanhooorebeke K, De Meyer SF. ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. *Blood* 2016; 127: 2337–45.

© 2017 The Authors. *Journal of Thrombosis and Haemostasis* published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
108 Sadler JE. Biochemistry and genetics of von Willebrand factor. *Annu Rev Biochem* 1998; 67: 395–424.
109 Zhou YF, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. *Blood* 2012; 120: 449–58.
110 Akiyama M, Nakayama D, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structure and enzymatic activity of an ADAMTS13 mutant with the East Asian-specific P475S polymorphism. *J Thromb Haemost* 2013; 11: 1399–406.
111 Tan K, Duquette M, Liu JH, Dong Y, Zhang R, Joachimiak A, Lawler J, Wang JH. Crystal structure of the TSP-1 type I repeats: a novel layered fold and its biological implication. *J Cell Biol* 2002; 159: 373–82.